AstraZeneca continues appeal against US court ruling over asthma drug

AstraZeneca said it will continue to "vigorously" defend the intellectual property rights protecting its Pulmicort Respules medicine.

AstraZeneca said it will continue to "vigorously" defend the intellectual property rights protecting its Pulmicort Respules medicine.

The company is appealing against a US court ruling that the patent protecting Pulmicort from rival drugs in the US is invalid.

The US Court of Appeal has issued a temporary injunction blocking generic manufacturers from distributing generic versions in the US until the court rules on AstraZeneca's appeal.

As a condition of the injunction, the court has also ordered that AstraZeneca post a bond in the amount of $72m.

"We intend to vigorously defend the intellectual property rights protecting Pulmicort Respules," said Executive Vice President of the company's North America division, Paul Hudson.

The patents protecting the drug expire in 2018, with paediatric exclusivity extending into 2019.

Separately, the group also announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey.

Under the agreement, AstraZeneca will acquire Omthera for $12.70 per share, or $323m.

Omthera is focused on the development of new therapies for abnormal levels of lipids in the blood, a condition known as dyslipidemia.

Its investigational product, Epanova, for the treatment of patients with very high triglycerides, has been shown to bolster levels of eicosapentaenoic acid and docosahexaenoic acid significantly in the blood.

The third phase of clinical studies have been completed on Epanova, a coated soft gelatin capsule containing a mixture of polyunsaturated free fatty acids derived from fish oils.

The studies revealed the drug helped to lower high levels of triglycerides and reduce non-high density cholesterol in combination with a statin for patients with high triglycerides.

Omthera is expected to file a new drug application (NDA) in the US for Epanova in mid-2013 for patients with severe hypertriglyceridemia.

"The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes," said AstraZeneca's Chief Executive Officer, Pascal Soriot.

"There is a clear need for effective and convenient alternatives to some of the existing treatments. Epanova offers real potential both as a distinctive monotherapy for the treatment of hypertriglyceridemia and in combination with Crestor for patients at high risk of adverse cardiovascular events.

"This is an exciting acquisition that clearly complements our existing portfolio in cardiovascular and metabolic disease, one of our core therapy areas."

RD

Recommended

How to be better at selling stocks
Investment strategy

How to be better at selling stocks

There is plenty of advice around about buying stocks, but not so much about when you should sell. John Stepek explains the two key things to know abou…
14 Jan 2022
Share tips of the week – 14 January
Share tips

Share tips of the week – 14 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
14 Jan 2022
Fintech: how to profit as technology transforms banking around the world
Share tips

Fintech: how to profit as technology transforms banking around the world

Financial technology – from apps to APIs to the cloud – is rapidly transforming financial services. This will spell doom for some incumbent firms, whi…
14 Jan 2022
Three solid assets to buy for a low interest-rate world
Share tips

Three solid assets to buy for a low interest-rate world

Professional investor Luke Hyde-Smith of the Waverton Real Assets Fund, highlights three alternative investments to diversify your portfolio.
14 Jan 2022

Most Popular

US inflation is at its highest since 1982. Why aren’t markets panicking?
Inflation

US inflation is at its highest since 1982. Why aren’t markets panicking?

US inflation is at 7% – the last time it was this high interest rates were at 14%. But instead of panicking, markets just shrugged. John Stepek explai…
13 Jan 2022
Five unexpected events that could shock the markets in 2022
Stockmarkets

Five unexpected events that could shock the markets in 2022

Forget Covid-19 – it’s the unexpected twists that will rattle markets in 2022, says Matthew Lynn. Here are five possibilities
31 Dec 2021
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022